Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
53 results about "Immune thrombocytopenia" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Immune thrombocytopenia purpura (ITP), also known as idiopathic thrombocytopenic purpura, is a type of thrombocytopenic purpura defined as an isolated low platelet count with a normal bone marrow in the absence of other causes of low platelets. It causes a characteristic red or purple bruise-like rash and an increased tendency to bleed. Two ...
Combination therapy with syk kinase inhibitor
The invention encompasses methods of increasing platelet levels in a patient having or at risk for immune thrombocytopenia comprising co-administering a Syk kinase inhibitor and a thrombopoietin receptor agonist, and methods of treating thrombocytopenia comprising co-administering a Syk kinase inhibitor and a thrombopoietin receptor agonist to a patient in need thereof, as well as pharmaceutical compositions for use in these methods.
Owner:RIGEL PHARMA
Application of anhydroicaritin in preparing drug for treating or preventing thrombopenia
ActiveCN104546823AGood treatment effectPositive therapeutic effectOrganic active ingredientsBlood disorderSide effectCurative effect
The invention relates to novel medical application of anhydroicaritin, particularly to application of anhydroicaritin in preparing a drug for treating or preventing thrombopenia, and belongs to the field of medicines. In order to overcome the technical defects that, in the prior art, the thrombopenia therapeutic drug is unabiding in therapeutic effect, high in possibility of recidivation during drug discontinuance and high in side effect, the invention provides a therapeutic drug containing anhydroicaritin. The therapeutic drug can greatly improve the platelet level of a parent when being used for treating thrombopenia, particularly immune thrombopenia, and has an obvious therapeutic effect; the therapeutic drug further has the obvious therapeutic effect on treating thrombopenia caused by myelosuppression; when being used for treating thrombopenia, anhydroicaritin has the advantages of being obvious in curative effect, low in treatment cost and little in toxic and side effects, and the therapeutic drug is quite suitable for clinical popularization and application.
Owner:LUNAN PHARMA GROUP CORPORATION
Moesin fragments associated with immune thrombocytopenia
ActiveUS20130316379A1Polypeptide with localisation/targeting motifPeptide/protein ingredientsMoesinImmune thrombocytopenia
The present application provides compositions and methods useful for detecting and monitoring immune thrombocytopenia.
Owner:SHANGHAI KEXIN BIOTECH
Compositions and methods for treating immune thrombocytopenia
PendingUS20200024344A1Raise countImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAgonistImmune thrombocytopenia
A method is disclosed for the treatment of human subjects diagnosed with immune thrombocytopenia (ITP). The method comprises administering to a human subject a human neonatal Fc receptor (hFcRn) antagonist, optionally in combination with standard-of-care ITP treatment. In certain embodiments, the hFcRn antagonist is efgartigimod (ARGX-113). Standard-of-care ITP treatment may comprise administration of corticosteroids, immunosuppressants, and / or thrombopoietin receptor (TPO-R) agonists.
Owner:ARGENX BV
Cytometric bead method for detecting blood platelet autoantibodies of immune thrombocytopenia
InactiveCN107422111AIncreased sensitivityContribute to clinical trial researchDisease diagnosisHuman plateletMicrosphere
The invention belongs to blood platelet clinical test and research and relates to a cytometric bead method for detecting blood platelet autoantibodies of immune thrombocytopenia. The cytometric bead method for detecting blood platelet autoantibodies of immune thrombocytopenia is high in sensitivity and specificity. The method comprises encapsulating beads through anti-human platelet membrane glycoprotein monoclonal antibodies, incubating platelet lysate and the encapsulated beads, and then adding in phycoerythrin marked goat antihuman immune globulin polyclonal antibodies to perform flow cytometry. If autoantibodies exist on the surface of platelets, a bead-platelet membrane glycoprotein monoclonal antibody-platelet membrane glycoprotein autoantibody-phycoerythrin marked goat antihuman immune globulin polyclonal antibody composite structure can be formed and embodied as increase of fluorescence intensity of detecting beads. The cytometric bead method for detecting blood platelet autoantibodies of immune thrombocytopenia is convenient to operate, mature in technology, high in sensitivity of blood platelet autoantibody detection and conductive to fundamental experimental research on platelet antibodies.
Owner:冀学斌
Chinese medicinal composition for treating thrombopenia as well as preparation method and application of composition
ActiveCN103054976AReduce bleedingShorten the timeBlood disorderExtracellular fluid disorderChronic idiopathic thrombocytopenic purpuraLithospermum
The invention discloses a Chinese medicinal composition for treating thrombopenia as well as a preparation method and application of the composition. The Chinese medicinal composition is prepared from madder and lithospermum in a mass ratio of (1:3)-(3:1). The composition is prepared by preparing and then uniformly mixing refined madder extract and refined lithospermum extract. Pharmacological and pharmacodynamic experimental results show that the composition of different dose groups can remarkably shorten the bleeding and clotting time of mice, the high or medium dose group can remarkably shorten the thrombin time (TT), the prothrombin time (PT) and the activated partial thromboplastin time (APTT) of chronic idiopathic thrombocytopenic purpura (ITP) model rats, and the high or medium dose group has an effect of remarkably improving the platelets of the rats. Thus, the Chinese medicinal composition can be used for preparing a medicinal preparation for treating the thrombopenia, and particularly can be used for preparing a medicinal preparation for treating immune thrombocytopenia.
Owner:SHANGHAI UNIV OF T C M
Use of icaritin in preparing medicament for preventing or treating hematocytopenia
ActiveUS20160250243A1Induce suppressionIncrease the number ofOrganic active ingredientsPeptide/protein ingredientsChemotherapeutic drugsMedicine
The present application relates to use of icaritin in preparing a medicament for preventing or treating hematocytopenia. Particularly, icaritin may be used to prevent or treat bone marrow suppression caused by chemotherapeutic drugs, and may also be used to prevent or treat thrombocytopenia, for example, immune thrombocytopenia.
Owner:LUNAN PHARMA GROUP CORPORATION
Traditional Chinese medicine composition for treating immune thrombocytopenia
InactiveCN104147419APromote circulationEnhance immune functionBlood disorderPlant ingredientsDiseaseLife quality
A traditional Chinese medicine composition for treating immune thrombocytopenia. The composition is composed of following traditional Chinese medicine raw materials including, by weight, 8-16 parts of herba schizonepetae, 5-9 parts of perilla frutescens, 6-12 parts of anemone chinensis, 8-12 parts of scrophularia ningpoensis, 6-15 parts of radix scutellariae, 5-10 parts of imperata cylindrica, 5-10 parts of angelica sinensis, 4-8 parts of rhizoma chuanxiong, 6-10 parts of radix lithospermi, 6-10 parts of lycium barbarum, 5-12 parts of radix aucklandiae, 5-10 parts of fructus ligustri lucidi and 4-8 parts of raw glycyrrhiza uralensis. The composition has effects of clearing heat and removing toxin, cooling blood and nourishing qi, improving blood circulation and enhancing body immune function. The composition can quickly alleviate symptoms when being used for treating the immune thrombocytopenia, can reduce repeated attack of diseases and can improve life quality of patients.
Owner:庄立
Chinese traditional medicine for treating thrombocytopenia
InactiveCN1557390AGood treatment effectElevated peripheral blood Bpc countUnknown materialsGranular deliverySide effectClinical trial
The thrombocytopenia treating Chinese medicine is orally taken preparation prepared with Chinese medicinal materials including notoginseng, bletilla tuber, cogongrass rhizome, and lotus root charcoal. Clinical test shows that the Chinese medicine of the present invention has obvious thrombocyte increasing and clinical symptom remitting effect on light and medium thrombocytopenia, including primary thrombocytopenia purpura caused by some medicine and has no toxic side effect. On serious thrombocytopenia, the present invention may assist chemical medicine treatment and reduce toxic side effect.
Owner:HENGXING PHARMA INST HEFEI
Application of biomarker of intestinal flora in preparation of product for diagnosing adult immune thrombocytopenia
ActiveCN113862382AAddressing key issues in early diagnosisMicrobiological testing/measurementMicroorganism based processesGenomic sequencingDisease
The invention discloses application of a biomarker of intestinal flora in preparation of a product for diagnosing adult immune thrombocytopenia. According to the application, shotgun-method metagenome sequencing is carried out on an adult immune thrombocytopenia patient, and florae with abundance difference from that of a normal person are found in an intestinal tract of the immune thrombocytopenia patient for the first time. Through further screening and analyzing the differential florae, it is found that the differential florae have higher sensitivity and specificity when being used for diagnosing diseases, and it is prompted that the early discovery and auxiliary diagnosis of the adult immune thrombocytopenia can be realized by detecting the relative abundance of the florae.
Owner:PEOPLES HOSPITAL PEKING UNIV
Use of icaritin in preparing medicament for preventing or treating hematocytopenia
ActiveUS10555962B2Induce suppressionIncrease the number ofOrganic active ingredientsPeptide/protein ingredientsChemotherapeutic drugsPharmaceutical drug
Owner:LUNAN PHARMA GROUP CORPORATION
Calf spleen extractive and application thereof to idiopathic thrombocytopenic purpura treatment
ActiveCN104352520AHigh yieldHigh activityUnknown materialsImmunological disordersBlood platelet countsSide effect
The invention provides a calf spleen extractive and application thereof to idiopathic thrombocytopenic purpura treatment. The preparation technology of the calf spleen extractive comprises the steps of preparation and freeze thawing of a homogenate, and pH adjustment and film filtration under the synergistic effect of combinative enzymes, as well as sterile filtering and filling. The extraction rate of polypeptide and ribose in the calf spleen extractive is greatly increased, and the glycopeptide ratio is set to be 80-87. The activity, capable of treating ITP, of the calf spleen extractive is verified through blood platelet counting and CD4<+>CD25<+>T proportion in all the immune organs, and the result shows that the calf spleen extractive can remarkably improve the blood platelet level by 50% than the original process, the hematopoietic function is improved and no toxic or side effects is generated.
Owner:JILIN UNIV +1
Chinese herbal medicine for curing chronic or intractable immune thrombocytopenia and preparation method of Chinese medicine preparation
ActiveCN102327587APromote absorptionGood for resisting exogenous pathogenic heatImmunological disordersBlood disorderMedicinal herbsEpimedium
The invention discloses Chinese herbal medicine for curing chronic or intractable immune thrombocytopenia and a preparation method of Chinese medicine preparation. The Chinese herbal medicine consists of the following raw materials by weight: 1 to 100 parts of radix pseudostellariae, 1 to 98 parts of fried atractylodes, 1 to 100 parts of glabrous greenbrier rhizome, 1 to 98 parts of baked licorice, 1 to 98 parts of cinnamon twig, 1 to 98 parts of radix paeoniae alba, 1 to 98 parts of cynomorium, 1 to 98 parts of epimedium, 1 to 98 parts of poison yam, 1 to 98 parts of dioscorea, 1 to 98 parts of flos lonicerae, 1 to 98 parts of herba taraxaci, 1 to 98 parts of ginger and 1 to 98 parts of jujube. The preparation method of the Chinese medicine preparation comprises the following steps that: (1) weighing the raw materials according to the compositions of the Chinese herbal medicine; and (2) placing the raw materials into a pot, filling water into the pot to immerse the herbs, starting steam to steam the herbs for two times, filtering the medicine lotion, and mixing the filtered medicine lotion. Due to the adoption of the Chinese herbal medicine, the efficacy on clinically curing chronic immune thrombocytopenia (cITP) patients or intractable immune thrombocytopenia (rITP) patients can be improved, and the abnormal immune state of the cITP patients or rITP patients can be effectively adjusted.
Owner:XIYUAN HOSPITAL OF CHINA ACAD OF CHINESE MEDICAL SCI
Immune thrombocytopenia lncRNA marker, kit and application
InactiveCN109207585AIncrease credibilityImprove stabilityMicrobiological testing/measurementDNA/RNA fragmentationTrue positive rateLess invasive
The invention provides an immune thrombocytopenia lncRNA marker, a kit and an application thereof. The lncRNA marker is LOC100506314, and its base sequence is shown in SEQ ID NO: 1. The base sequenceof the primer of the lncRNA marker is shown in SEQ ID NO: 2 and SEQ ID NO: 3. LncRNA markers and primers thereof are used for preparing drugs for inhibiting immune thrombocytopenia or for preparing immune thrombocytopenia auxiliary diagnostic kits. The lncRNA marker can be used for judging the progress and severity of immune thrombocytopenia. The LOC100506314 primer and diagnostic reagent kit anddetection method developed on the basis of LOC100506314 are easy to operate, less invasive, high sensitivity and specificity, and can be used to monitor the disease progression clinically. The LOC100506314 primer and diagnostic reagent kit has an auxiliary diagnostic effect on the disease onset, drug efficacy and prognosis, and has obvious clinical application value.
Owner:中国人民解放军第一OO医院
Moesin fragments associated with immune thrombocytopenia
The present application provides compositions and methods useful for detecting and monitoring immune thrombocytopenia.
Owner:SHANGHAI KEXIN BIOTECH
Traditional Chinese medicine composition for treating idiopathic thrombocytopenic purpura
InactiveCN104173563AControl bleeding symptomsLift countBlood disorderPlant ingredientsBlood platelet countsLigustrum vulgare
The invention relates to a traditional Chinese medicine composition for treating idiopathic thrombocytopenic purpura. The traditional Chinese medicine composition is prepared from the following raw pharmaceutical materials in parts by weight: 20-28 parts of raw milkvetch root, 15-20 parts of prepared ligustrum lucidum, 10-15 parts of atractylodes macrocephala, 12-18 parts of raw rehmannia root, 15-20 parts of dodder seed, 12-18 parts of tree peony bark, 12-18 parts of Jiangnan herba selaginellae, 12-18 parts of herba agrimoniae, 12-18 parts of aizoon stonecrop and 4-8 parts of prepared liquorice root. The invention further provides application of the traditional Chinese medicine composition. The traditional Chinese medicine composition has the advantages that the compatibility of the traditional Chinese medicine composition disclosed by the invention accords with the principle of monarch-and-minister-and-assistant-and-guide of the traditional Chinese medicine, the traditional Chinese medicine composition can effectively control the bleeding symptom of a sufferer, improve the quality of life and increase the number of platelets and has a remarkable treatment effect on idiopathic thrombocytopenic purpura, and no adverse reaction is caused, so that the traditional Chinese medicine composition has broad development and application prospects and is suitable for further popularization and application.
Owner:YUEYANG INTEGRATED TRADITIONAL CHINESE & WESTERN MEDICINE HOSPITAL SHANGHAI UNIV OF CHINESE TRADITIONAL MEDICINE
Application of artemisinin compound in preparation of drugs for treating ITP
InactiveCN109939104ALow cost of treatmentReduce doseOrganic active ingredientsImmunological disordersBlood platelet countsGlucocorticoid
The invention discloses application of an artemisinin compound in preparation of drugs for treating ITP. It is unexpectedly discovered in clinical trials that blood platelet count holding time can beprolonged when drugs of artemisinin, especially artesunate or dihydroartemisinin treat patients with immune thrombocytopenia and patients with relapse of the immune thrombocytopenia, and it is indicated that the artemisinin drugs have a good therapeutic effect on the immune thrombocytopenia. Further studies show that the combination of the artemisinin drugs and other drugs, such as the combinationof the artemisinin drugs and glucocorticoids, can further reduce the dosage of glucocorticoid, gamma globulin and the like for treatment, thereby reducing the treatment cost of the patients and reducing the probability of significant complications. Reticulocytes as a toxicity sensitive index of the artemisinin drugs are strictly observed by the inventor, it is found that no significant differenceexists before and after the treatment, and it is further showed that the artemisinin drugs have good safety.
Owner:广州博奥技术有限公司
Pharmaceutical composition for treating primary immune thrombocytopenia and preparation method thereof
InactiveCN110840951AImprove efficacySignificant effectOrganic active ingredientsUnknown materialsSide effectRadix Astragali seu Hedysari
The invention relates to a pharmaceutical composition for treating primary immune thrombocytopenia and a preparation method thereof. The pharmaceutical composition is characterized by comprising, by weight, 1-80 parts of mycophenolate mofetil, 0.5-20 parts of pseudo-ginseng, 1-40 parts of radix astragali, 0.5-20 parts of caulis spatholobi, 0.5-20 parts of poria cocos, 0.5-20 parts of rhizoma atractylodis macrocephalae, 1-20 parts of colla corii asini, 1-20 parts of radix codonopsis, 1-10 parts of radix glycyrrhizae preparata and 1-10 parts of radix rubiae. The pharmaceutical composition has the advantages that by the joint effect of the mycophenolate mofetil and the traditional Chinese medicine materials, the primary immune thrombocytopenia can be treated, the total curative effect of themedicine is increased, and the pharmaceutical composition is few in untoward reaction, low in cost, capable of lowering the side effects of the mycophenolate mofetil on human bodies, small in toxic and side effects and evident in curative effect.
Owner:ZHUOHE PHARM GRP CO LTD
Novel method for drug loading system constructed by means of sensitization blood platelets for treating immune thrombocytopenia
InactiveCN108339123AGood biocompatibilityIncrease contentOrganic active ingredientsPharmaceutical non-active ingredientsSide effectBiocompatibility Testing
The invention discloses a novel method for a drug loading system constructed by means of sensitization blood platelets for treating immune thrombocytopenia. The method comprises the steps that firstly, whole blood is anti-coagulated and centrifuged to obtain platelet rich plasma, then, deep centrifuging washing is performed to obtain washed platelets, the washed platelets react with CD41 monoclonal antibody oscillation, and centrifuging is performed to obtain the CD41 monoclonal antibody modified target macrophage sensitization blood platelets; then, the sensitization blood platelets and an immunosuppressor or a chemically modified cytotoxic drugs are mixed and incubated, centrifuging and purifying are performed, and finally the sensitization blood platelet drug loading system carrying drug for resisting immune thrombocytopenia is obtained. The drug loading system has the advantages of being abundant in source, high in drug loading rate, good in biocompatibility, high in targeting, long in cycle time and the like, the drug can precisely target macrophage, and the concentration of the drug inside the macrophage is increased, so that the drug curative effect is improved, and meanwhile the toxic and side effect on normal tissue is effectively relieved.
Owner:NANJING DRUM TOWER HOSPITAL
Compositions and methods for treating immune thrombocytopenia
Owner:ARGENX BVBA
MiRNA marker of immune thrombocytopenia, kit and application
InactiveCN109295213ALess traumaticSimple and fast operationMicrobiological testing/measurementDNA/RNA fragmentationPhases of clinical researchImmune thrombocytopenia
The invention provides a miRNA marker of immune thrombocytopenia, a kit and application. The miRNA marker is hsa-miR-302e, the base sequence of the marker is shown as SEQ ID NO:1. The base sequences of the miRNA marker's primers are shown as SEQ ID NO:2 and SEQ ID NO:3. The miRNA marker and the primers thereof can be used for preparation of drugs inhibiting immune thrombocytopenia or preparation of immune thrombocytopenia auxiliary diagnosis kit. The miRNA marker can be used for judging the progress and severity of immune thrombocytopenia. The hsa-miR-302e primers, diagnosis kit and detectionmethod developed based on the miRNA marker have the characteristics of simple operation, little trauma to examinees, high sensitivity and strong specificity, and can be used for diagnosis of immune thrombocytopenia at the early stage and different stages, and have obvious clinical application value.
Owner:中国人民解放军第一00医院
Application of G-CSF in treatment of dysimmunity of ITP patient
InactiveCN109395063AReduced potential therapeutic effectReduce Th1/Th2 ratioPeptide/protein ingredientsImmunological disordersTreatment effectMedicine
The invention relates to new use of a drug, in particular to a G-CSF regulating the ratio of Th1 / Th2 cells of PBMCs in an ITP patient to treat ITP. In vitro experiments demonstrate that the G-CSF canreduce the Th1 / Th2 ratio in the ITP patient in a dose-dependent manner. The decrease in the ratio of T-bet / GATA-3 demonstrates that the G-CSF can reduce the Th1 / Th2 ratio indirectly. The study shows for the first time the potential treatment effect of the G-CSF on the ITP patient.
Owner:PEOPLES HOSPITAL OF HENAN PROV
Traditional Chinese medicine composition for treating primary immune thrombocytopenia
InactiveCN111821395ANo bleeding symptomsUnknown materialsBlood disorderSmoked PlumEssential Thrombocytopenia
The invention discloses a traditional Chinese medicine composition for treating primary immune thrombocytopenia. Active ingredients of the traditional Chinese medicine composition are prepared from the following crude drugs in parts by weight: 50-70 parts of hairyvein agrimonia herbs, 5-15 parts of platycodon roots, 5-15 parts of smoked plums, 5-15 parts of common aucklandia roots, 10-30 parts ofprepared radix glycyrrhizae,10-30 pats of parched white atractylodes rhizomes, 10-30 parts of debark peony roots, 10- 30 parts of areca seeds, 20-40 parts of fried coix seeds, 20-40 parts of poria cocos, 20-40 parts of atrina glass, 20-40 parts of milkvetch roots, 20-40 parts of codonopsis pilosula, 5-15 parts of tortoise-plastron glues and 5-15 parts of largetrifoliolious bugbane rhizomes. The invention has effects in stopping bleeding, increasing platelets and regulating immunity, and is fast in taking effect, exact in curative effect, not easy to relapse and free of toxic side effects. After clinical practice, the traditional Chinese medicine composition shows a cure rate as high as 98%, and the traditional Chinese medicine composition is the choice drug for treating the primary immunethrombocytopenia.
Owner:张春枝
Traditional Chinese herbal medicine for curing chronic or intractable immune thrombocytopenia and preparation method of Traditional Chinese medicine preparation
ActiveCN102327587BPromote absorptionGood for resisting exogenous pathogenic heatImmunological disordersBlood disorderMedicinal herbsEpimedium
Owner:XIYUAN HOSPITAL OF CHINA ACAD OF CHINESE MEDICAL SCI
Chinese traditional medicine for treating thrombocytopenia
InactiveCN100337671CGood treatment effectElevated peripheral blood Bpc countGranular deliveryBlood disorderSide effectClinical trial
The thrombocytopenia treating Chinese medicine is orally taken preparation prepared with Chinese medicinal materials including notoginseng, bletilla tuber, cogongrass rhizome, and lotus root charcoal. Clinical test shows that the Chinese medicine of the present invention has obvious thrombocyte increasing and clinical symptom remitting effect on light and medium thrombocytopenia, including primary thrombocytopenia purpura caused by some medicine and has no toxic side effect. On serious thrombocytopenia, the present invention may assist chemical medicine treatment and reduce toxic side effect.
Owner:HENGXING PHARMA INST HEFEI
Detection method for children immune thrombocytopenia
PendingCN111613323AImprove the level of diagnosis and treatmentAchieve interactionMedical data miningHealth-index calculationNewly diagnosedClinical exam
The invention discloses a detection method for children immune thrombocytopenia, and particularly relates to the field of thrombocytopenia detection methods. The method comprises the following specific detection steps: S1, establishing a multi-center child ITP research cooperation group; S2, standardizing ITP clinical examination diagnosis and chronic prejudgment standards of children; S3, formulating and implementing an advanced ITP precise layering treatment scheme: evaluating a plurality of newly diagnosed ITP child patients entering the group according to the scheme; S4, performing follow-up visit and statistical analysis; and S5, performing multi-center random control clinical test. According to the invention, a child ITP diagnosis and treatment research cooperation group is established, a core expert group is established to manage the cooperation group, a unified and standard diagnosis and treatment scheme is implemented, a child ITP diagnosis and treatment research network withcooperative access and rapid response is formed, and the child ITP diagnosis and treatment research network is radiated downwards to primary hospitals by taking member hospitals as backbones; throughscientific research and innovation, key clinical problems existing in current ITP treatment are promoted to be solved, and the overall diagnosis and treatment level of children ITP in China is greatlyimproved.
Owner:BEIJING CHILDRENS HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
Preparation method for human-mouse chimeric monoclonal antibodies of human CD20
InactiveCN104861065AReduce adverse reactionsGood curative effectImmunoglobulins against cell receptors/antigens/surface-determinantsImmunological disordersBALB/cCD20
The invention discloses a preparation method for human-mouse chimeric monoclonal antibodies of human CD20. SPF-level female Balb / c mice 6-12 weeks old are employed, and the immunization flows are the same as immunization flows of general serum preparation; the immuned mice are subjected to pretreatment, B cells and myeloma cells are subjected to cell fusion through a PEG method; HAT is employed for selective culture, hybridomas are obtained; the cell culture supernatant fluid is detected, and positive clone screening is carried out; hybridoma cloning is carried out; cryopreservation and recovery of the hybridomas are carried out; human-mouse chimeric monoclonal antibodies of human CD20 are produced for a large scale. An embodiment employing a small dose of rituximab for treating immune thrombocytopenia supports that combination of rituximab and other medicines may obtain better effects in clinic application compared with a single medicine, has good treatment effects in immune thrombocytopenia treatment, has small adverse reactions, and can be employed as an effective second-line treatment means.
Owner:刘景华
Suppressive macrophages, C-reactive protein and the treatment of systemic lupus erythematosus and immune thrombocytopenic
InactiveUS8263556B2Increase platelet countRelieve symptomsOrganic active ingredientsBiocideCns effectsDendritic cell
The present invention relates to the use of suppressive macrophage or dendritic cells (activated with C-reactive protein or CRP-related compounds), for the treatment of various disease states and conditions associated with immune thrombocytopenic purpura (ITP) and / or systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with systemic lupus erythematosus or ITP will have an outbreak is an additional aspect of the present invention. In the case of ITP, methods of the present invention are used to increase platelet counts in the treated patient. In addition, in the case of ITP, the present invention relates to the use of CRP or a CRP-related compound in the absence of suppressive macrophages for the treatment of ITP.
Owner:STC UNM
Traditional Chinese medicine for treating Yin-deficiency and excessive fire type children primary immune thrombocytopenia
ActiveCN108853263AReduce bleeding frequencyGood curative effectDispersion deliveryBlood disorderTreatment effectCurative effect
The invention aims at providing a traditional Chinese medicine for treating Yin-deficiency and excessive fire type children primary immune thrombocytopenia. The traditional Chinese medicine is prepared from the following crude drugs by weight: 6 to 15g of radix rehmanniae recen, 6 to 15g of cortex moutan radicis, 6 to 15g of fructus lycii, 6 to 15g of fructus schisandrae chinensis, 6 to 15g of herba agrimoniae, 5 to 12g of lithospermum carbon, 5 to 12g of rubia cordifolia, 5 to 12g of oroxyli, 6 to 15g of radix isatidis, and 2 to 6g of honey-fried liquorice root. The traditional Chinese medicine has the advantages that by adopting the pure traditional Chinese medicines, the components are mutually complementary; the effects of nourishing Yin and clearing heat as well as cooling blood and calming meridians are realized; by reducing the repeated infection times of a patient and regulating the immunity, the platelets are stabilized within the normal range for a long time, the bleeding frequency is reduced, the treatment effect is good, and the safety in use is realized; the traditional Chinese medicine is an innovation in medicines for treating Yin-deficiency and excessive fire type children primary immune thrombocytopenia; the economic and social effects are obvious.
Owner:HENAN UNIV OF CHINESE MEDICINE
Composition enriched in Anti-a and/or Anti-b polyclonal immunoglobulins for use in the treatment of autoimmune diseases or polycythemia
InactiveUS20180142036A1Induce destructionLimiting and preventing destructionImmunoglobulins against blood group antigensPeptide/protein ingredientsAutoimmune conditionAutoimmune disease
The invention relates to a composition strongly enriched with anti-A and / or anti-B polyclonal immunoglobulins, comprising polyclonal human immunoglobulins, characterised in that at least 80 wt.-% of the polyclonal human immunoglobulins present in the composition are anti-A or anti-B polyclonal human immunoglobulins, for use as a drug, particularly in the treatment of polycythemia and / or autoimmune diseases, and in particular peripheral autoimmune thrombocytopenia.
Owner:LABE FR DU FRACTIONNEMENT & DES BIOTECH SA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com